• About
  • Submit Article/PR
  • Contact
Friday, March 24, 2023
No Result
View All Result
  • Login
The Healthcare Daily
WHO COVID DASHBOARD
  • Home
  • News
    • All
    • Biotech
    • By Speciality
    • Generic Drugs
    • Insurance
    • Investment
    • Medical Tourism
    • Pharma
    What-Chronic-Disease-Management-Is-All-About-How-to-Deal-with-It-Healthcare-Daily

    What Chronic Disease Management Is All About & How to Deal with It

    cancer-cure-TheHealthcareDaily

    Cancer Cure: Is there a cure for it?

    Womens-Reproductive-Rights-Around-the-world-Healthcare-Daily

    Women’s Reproductive Rights Around the World : Rights 101

    Everything-about-Telehealth-reimbursement-and-insurance-coverage-Healthcare-Daily

    Absolutely Everything about Telehealth Reimbursement and Coverage : Healthcare 101

    Everything-about-Personalized-Medicine-in-2023-Healthcare-Daily

    Everything about Personalized Medicine in 2023

    Healthcare cost containment and insurance reform

    Healthcare cost containment and insurance reform

    Understanding Chronic Diseases: Symptoms, Causes, and Treatment Options

    The Most Common Dental Mistakes in Healthcare Industry

    The 6 Most Common Dental Mistakes in Healthcare Industry

    How To Get a Dental Checkup for Free (or Cheap)

    How To Get a Dental Checkup for Free (or Cheap)

  • Insights
    • All
    • Analysis
    • Interview
    • Opinion
    • Reports
    Workforce-Diversity-and-its-5-Benefits-in-healthcare-Daily

    Workforce Diversity and it’s 5 Benefits in healthcare

    Healthcare-Affordability-in-United-States-Healthcare-101-Daily

    Healthcare Affordability in United States : Healthcare 101

    The-Benefits-and-Challenges-of-Data-and-Analytics-in-Healthcare-Daily

    The Benefits and Challenges of Data and Analytics in Healthcare

    Healthcare-Industry-At-A-Glance-Healthcare-DAily

    Healthcare Industry At A Glance

    7-Reasons-Millennials-Are-The-Most-Disruptive-Generation-Yet-Healthcare-Daily

    7 Reasons Millennials Are The Most Disruptive Generation Yet

    Technological-challenges-faced-by-pharma-companies-today-Healthcare-Daily

    Technological challenges faced by Pharma Companies Today

    Senior living options in Canada

    Senior living options in Canada in 2022

    A Guide to Medical Tourism in India: Everything You Need to Know

    A Guide to Medical Tourism in India: Everything You Need to Know

    5 Things to know before adopting a child

    Adoption: 5 Things to know before going for a successful child adoption

  • HealthTech
    • All
    • Hardware
    • Innovation
    • Software
    Overview-of-healthcare-hackathons-and-competitions-focused-on-healthcare-innovation-thehealthcaredaily

    Overview of healthcare hackathons and competitions focused on healthcare innovation

    Everything-about-Telehealth-reimbursement-and-insurance-coverage-Healthcare-Daily

    Absolutely Everything about Telehealth Reimbursement and Coverage : Healthcare 101

    Everything-about-Personalized-Medicine-in-2023-Healthcare-Daily

    Everything about Personalized Medicine in 2023

    5-Amazing-Advancements-in-Medical-Technology-2023-Healthcare-Daily

    5 Amazing Advancements in Medical Technology 2023

    Pros-and-Cons-of-Telemedicine-Healthcare-Daily

    Pros and Cons of Telemedicine in Healthcare 2023

    The-Benefits-and-Challenges-of-Data-and-Analytics-in-Healthcare-Daily

    The Benefits and Challenges of Data and Analytics in Healthcare

    Healthcare workforce and talent management

    Healthcare workforce and talent management

    Healthcare cost containment and insurance reform

    Healthcare cost containment and insurance reform

    Telehealth and digital health solutions

    Telehealth and digital health solutions

  • Pharma
  • Events
  • NewsMakers
  • World
  • Home
  • News
    • All
    • Biotech
    • By Speciality
    • Generic Drugs
    • Insurance
    • Investment
    • Medical Tourism
    • Pharma
    What-Chronic-Disease-Management-Is-All-About-How-to-Deal-with-It-Healthcare-Daily

    What Chronic Disease Management Is All About & How to Deal with It

    cancer-cure-TheHealthcareDaily

    Cancer Cure: Is there a cure for it?

    Womens-Reproductive-Rights-Around-the-world-Healthcare-Daily

    Women’s Reproductive Rights Around the World : Rights 101

    Everything-about-Telehealth-reimbursement-and-insurance-coverage-Healthcare-Daily

    Absolutely Everything about Telehealth Reimbursement and Coverage : Healthcare 101

    Everything-about-Personalized-Medicine-in-2023-Healthcare-Daily

    Everything about Personalized Medicine in 2023

    Healthcare cost containment and insurance reform

    Healthcare cost containment and insurance reform

    Understanding Chronic Diseases: Symptoms, Causes, and Treatment Options

    The Most Common Dental Mistakes in Healthcare Industry

    The 6 Most Common Dental Mistakes in Healthcare Industry

    How To Get a Dental Checkup for Free (or Cheap)

    How To Get a Dental Checkup for Free (or Cheap)

  • Insights
    • All
    • Analysis
    • Interview
    • Opinion
    • Reports
    Workforce-Diversity-and-its-5-Benefits-in-healthcare-Daily

    Workforce Diversity and it’s 5 Benefits in healthcare

    Healthcare-Affordability-in-United-States-Healthcare-101-Daily

    Healthcare Affordability in United States : Healthcare 101

    The-Benefits-and-Challenges-of-Data-and-Analytics-in-Healthcare-Daily

    The Benefits and Challenges of Data and Analytics in Healthcare

    Healthcare-Industry-At-A-Glance-Healthcare-DAily

    Healthcare Industry At A Glance

    7-Reasons-Millennials-Are-The-Most-Disruptive-Generation-Yet-Healthcare-Daily

    7 Reasons Millennials Are The Most Disruptive Generation Yet

    Technological-challenges-faced-by-pharma-companies-today-Healthcare-Daily

    Technological challenges faced by Pharma Companies Today

    Senior living options in Canada

    Senior living options in Canada in 2022

    A Guide to Medical Tourism in India: Everything You Need to Know

    A Guide to Medical Tourism in India: Everything You Need to Know

    5 Things to know before adopting a child

    Adoption: 5 Things to know before going for a successful child adoption

  • HealthTech
    • All
    • Hardware
    • Innovation
    • Software
    Overview-of-healthcare-hackathons-and-competitions-focused-on-healthcare-innovation-thehealthcaredaily

    Overview of healthcare hackathons and competitions focused on healthcare innovation

    Everything-about-Telehealth-reimbursement-and-insurance-coverage-Healthcare-Daily

    Absolutely Everything about Telehealth Reimbursement and Coverage : Healthcare 101

    Everything-about-Personalized-Medicine-in-2023-Healthcare-Daily

    Everything about Personalized Medicine in 2023

    5-Amazing-Advancements-in-Medical-Technology-2023-Healthcare-Daily

    5 Amazing Advancements in Medical Technology 2023

    Pros-and-Cons-of-Telemedicine-Healthcare-Daily

    Pros and Cons of Telemedicine in Healthcare 2023

    The-Benefits-and-Challenges-of-Data-and-Analytics-in-Healthcare-Daily

    The Benefits and Challenges of Data and Analytics in Healthcare

    Healthcare workforce and talent management

    Healthcare workforce and talent management

    Healthcare cost containment and insurance reform

    Healthcare cost containment and insurance reform

    Telehealth and digital health solutions

    Telehealth and digital health solutions

  • Pharma
  • Events
  • NewsMakers
  • World
No Result
View All Result
The Healthcare Daily
No Result
View All Result

Eli Lilly’s Olumniant (barcitinab) receives EUA from the US FDA for COVID-19 treatment

Baricitinib, with remdesivir, was shown to decrease time to cure within 29 days after starting treatment juxtaposed to patients who got a placebo with remdesivir.

by Jasleen Arora
November 20, 2020
in Covid-19, News, Reports, Uncategorized
Reading Time: 3 mins read
0
Eli Lilly’s Olumniant (barcitinab) receives EUA from the US FDA for COVID-19 treatment
0
SHARES
Share on FacebookShare on Twitter
  • USFDA published an Emergency Use Authorisation (EUA) for the drug Baricitinib.
  • Remdesivir is an FDA-approved intravenous antiviral drug for use in adult and pediatric patients.
  • Remdesivir also remains sanctioned for emergency use for the treatment of suspected or laboratory-confirmed COVID-19.

 

THDNewsDesk: The US Food and Drug Administration (USFDA) published an Emergency Use Authorisation (EUA) for the drug Baricitinib. Incorporation with remdesivir, for the treatment of presumed or laboratory-confirmed COVID-19. In hospitalised adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Baricitinib, with remdesivir, was shown to decrease time to cure within 29 days after starting treatment juxtaposed to patients who got a placebo with remdesivir. The safety and efficiency of this investigational therapy for use in the treatment of COVID-19 persists to be assessed. Baricitinib is not sanctioned or accepted as a stand-alone treatment for COVID-19.

Baricitinib is a Janus kinase inhibitor, which prevents the action of one or more of a particular family of enzymes, intervening with the pathway that drives to inflammation. Baricitinib is a prescription oral tablet medication that is FDA-approved (and sold under the brand name Olumiant) for the therapy of adequate to critically active rheumatoid arthritis. Under today’s EUA, the FDA is approving the emergency use of baricitinib, in combination with remdesivir, for the assistance of certain hospitalised patients with speculated or laboratory-confirmed COVID-19.

Remdesivir is an FDA-approved (and sold under the brand name Veklury) intravenous antiviral drug for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalisation. Remdesivir also remains sanctioned for emergency use for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalised paediatric patients weighing 3.5 kg to less than 40 kg. It can also be used, for hospitalised paediatric patients of less than 12 years of age weighing at least 3.5 kg.

Based on the FDA’s analysis of the entirety of the scientific evidence accessible, the agency has concluded that it is feasible to believe that baricitinib, in combination with remdesivir, may be efficient in treating COVID-19 for the authorised population. When used under the prescribed conditions of the EUA to treat COVID-19, the known and possible advantages of baricitinib exceed the identified and inherent risks for the drug. There are no sufficient, sanctioned and feasible alternative treatments to baricitinib when utilised with remdesivir, for the treatment of speculated or laboratory-confirmed COVID-19 in hospitalised adults and paediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or ECMO.

The data backing this EUA for baricitinib combined with remdesivir are established, on a randomised, double-blind, placebo-controlled clinical trial (ACTT-2). The National Institute of Allergy and Infectious Diseases (NIAID) led the trial. This clinical test assessed whether baricitinib influenced the patients who were also receiving remdesivir to heal from COVID-19. The test followed subjects for 29 days and involved 1,033 patients with mild or critical COVID-19. 515 patients took baricitinib plus remdesivir, and 518 patients took placebo plus remdesivir. Recovery was defined, as either being released from the hospital or being hospitalised but not demanding supplemental oxygen and no longer needing ongoing medical care. The median time to healing from COVID-19 was seven days for baricitinib plus remdesivir and eight days for placebo plus remdesivir. The probabilities of a patient’s status advancing to death or being ventilated at day 29 were weaker in the baricitinib plus remdesivir group versus the placebo plus remdesivir group. The chances of clinical improvement at day 15 were higher in the baricitinib plus remdesivir group versus the placebo plus remdesivir group. For all of these endpoints, the results were scientifically notable.

Source-Express Pharma

Jasleen Arora

Jasleen Arora

Jasleen is pursuing a Master's in English Literature at the University of Delhi. She is an avid reader who believes that everyone has a story, a day dreamer who loves to live in the moment, and a music explorer who will stick to her old playlist. 'Irony lies therein'. That’s what her autobiography will be called.

Next Post
SII CEO Adar Poonawalla says Oxford’s Covid vaccine candidate would be available by April 2021

SII CEO Adar Poonawalla says Oxford's Covid vaccine candidate would be available by April 2021

Recommended

Brazilian President Bolsnaro spurns China's COVID vaccine

Brazilian President Bolsnaro spurns China’s COVID vaccine

2 years ago
Healthcare in lockdown

Healthcare In Lockdown

1 year ago

About Us

A daily dose of news, views, opinions, and actionable information from the global healthcare industry. Our newsletter is available for a limited audience. If you are interested to write or contribute to this portal then please get in touch.

Contact Us

Medianiti Ltd, Brooklands Business Park, Wellington Way, Weybridge KT13 0TT,
United Kingdom
General: hello@thehealthcaredaily.com

Important Links

  • Home
  • World
  • Business
  • Health

Recent News

Overview of healthcare hackathons and competitions focused on healthcare innovation

Exclusive interviews with healthcare thought leaders and executives

  • About
  • Submit Article/PR
  • Contact

© 2020 THP - A Medianiti Venture.

No Result
View All Result
  • Home
  • World
  • Business
  • Health

© 2020 THP - A Medianiti Venture.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In